<DOC>
	<DOCNO>NCT02441803</DOCNO>
	<brief_summary>Objectives : Primary Objectives : 1 . To determine safety feasibility allogeneic hematopoietic stem cell transplantation ( AHSCT ) initial salvage treatment patient primary induction failure ( PIF ) acute myeloid leukemia ( AML ) . 2 . To determine efficacy AHSCT follow decitabine , clofarabine , idarubicin , cytarabine ( DCIA ) salvage chemotherapy evaluate overall response rate ( RR ) , define complete response ( CR ) CR without platelet recovery ( CRp ) CR insufficient hematological recovery ( CRi ) . Secondary Objectives : 1 . To determine percentage patient PIF AML eligible AHSCT 2 course induction chemotherapy . 2 . To determine early treatment-related mortality ( TRM ) ( within first 4 week first salvage chemotherapy regimen DCIA day 100 TRM AHSCT . 3 . To determine efficacy DCIA regimen salvage chemotherapy patient PIF AML ( % patient achieve &lt; /=5 % bone marrow blast prior AHSCT . 4 . To determine TRM 1 year , relapse rate ( RR ) , overall survival ( OS ) event-free survival ( EFS ) patient PIF AML treat DCIA follow early AHSCT .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation ( AlloSCT ) Initial Salvage Therapy Induction Failure Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Salvage Chemotherapy Before Transplant : Study Drug Administration : On Days 1-5 , receive decitabine 1 time day vein 1-3 hour . On Days 6-10 : - You receive cytarabine 1 time day vein 1-3 hour . - On Days 6-8 , receive idarubicin 1 time day vein 30 minute . - On Days 6-9 , receive clofarabine 1 time day vein 1-2 hour . Study Visits : After last study drug dose : - Blood ( 2 teaspoon ) draw check kidney liver function . - You echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan check heart function . - You lung function test . On Day 21 ( +/- 7 day ) , bone marrow biopsy/aspirate check status disease . To collect bone marrow biopsy/aspirate , area hip numb anesthetic , small amount bone bone marrow withdrawn large needle . If result bone marrow biopsy/aspirate , blood test , heart lung function test show eligible receive allogeneic stem cell transplant , ask sign separate inform consent transplant . If result bone marrow aspirate/biopsy , blood test , heart lung function test show eligible receive allogeneic stem cell transplant receive . The study staff call ask feel drug may take every 3 month 2 year last study drug dose . These call last 5 minute . If find NOT eligible receive allogeneic stem cell transplant , doctor discus treatment option . This investigational study . Decitabine FDA approve commercially available treat myelodysplastic syndrome ( MDS ) . Clofarabine FDA approve commercially available treat ALL child . Idarubicin cytarabine FDA approve commercially available treat AML . The study drug combination investigational . Up 75 participant enrol study . All take part MD Anderson . Stem Cell Transplant : Study Drug Administration , Pharmacokinetic ( PK ) Testing , Stem Cell Transplant : For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . You receive dose busulfan vein 45 minute 1 hour outpatient inpatient Day -8 . With first busulfan infusion , blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test 11 time 11 hour receive first dose busulfan . PK test measure amount study drug body different time point . The study staff tell blood test schedule . Test dos use study body break busulfan decide dose busulfan receive Days -6 -3 . A heparin lock line place vein PK test low number needle stick need draws . If reason possible PK test perform , receive standard dose busulfan . On Day -7 , rest . On Days -6 -3 , receive fludarabine vein 1 hour , clofarabine vein 1 hour , busulfan vein 3 hour . On Days -3 -2 , receive stem cell match unrelated donor , receive ATG vein 4 hour day . On Day -2 , receive stem cell haploidentical donor , receive total body irradiation ( TBI ) one time . TBI involve delivery high dos radiation design destroy cancer cell and/or low immune system order low risk body reject new stem cell . On Day -2 , receive tacrolimus vein 24 hour every day able take mouth . Tacrolimus design weaken immune system low risk graft-versus-host-disease ( GVHD - reaction donor 's immune cell body ) . After able take tacrolimus mouth , take every day 6 month , doctor think safe stop . On Day -1 , rest . If receive stem cell match sibling donor , rest Days -2 -1 . On Day 0 , receive donor 's stem cell vein . The infusion last anywhere 30 minute several hour . If receive stem cell haploidentical donor : After stem cell infusion , receive tacrolimus help low risk GVHD . Tacrolimus give vein non-stop 2 week . After 2 week take tacrolimus vein , take tacrolimus mouth pill least 4 month transplant . On Days +3 +4 , receive cyclophosphamide vein 3 hour . Cyclophosphamide give low immune system order low risk GVHD . If receive stem cell match sibling match unrelated donor : On Days +1 , +3 , +6 , +11 , receive methotrexate vein 30 minute . Methotrexate give help prevent GVHD . Study Testing : Before send home hospital and/or clinic , receive additional write instruction . These instruction include often come hospital/clinic , standard drug take home , side effect may . After finish chemotherapy transplant , follow-up care routine standard care follow-up patient receive allogeneic stem cell transplantation receive . At visit , physical exam . You ask side effect may . Blood ( 1 tablespoon ) drawn routine test . If doctor think need , bone marrow aspiration check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Length Treatment : After 2 year , participation study . You may take study early disease get bad , transplant `` take '' ( graft failure ) , unable follow study direction , doctor think best interest , study stop , choose leave study early . If reason want leave study early , must talk study doctor . It may life-threatening leave study start receive study drug receive stem cell transplant blood cell count dangerously low . This investigational study . Decitabine FDA approve commercially available treat myelodysplastic syndrome ( MDS ) . Clofarabine FDA approve commercially available treat ALL child . Idarubicin cytarabine FDA approve commercially available treat AML . The study drug combination investigational . Adding transplant early course leukemia treatment investigational . Up 75 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients age 1860 year . 2 . Patients diagnosis AML , judge primary refractory 2 course induction HDACbased regimen ( &gt; 5 % blast day 21 ( +/7 day ) bone marrow aspirate and/or biopsy begin induction chemotherapy , 42 day ) . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 . 4 . Adequate major organ function : , define : ) Serum creatinine &lt; /= 3 mg/dL ; b ) Total bilirubin &lt; /= 2.5 mg/dL ; c ) ALT ( SGPT ) &lt; /= 3 x ULN &lt; /= 5 x ULN related disease ; ) Cardiac ejection fraction &gt; /= 40 % ( either ECHO MUGA ) . 5 . Willingness allogeneic transplant . 6 . Patient patient 's legal representative able provide write informed consent . 7 . Patients required meet follow criterion proceed AHSCT : 8 . Donor criterion : Availability donor either HLA match sibling donor ( MSD ) haploidentical ( 59/10 HLA match ) ; alternatively 8/8 HLA match unrelated donor ( MUD ) high resolution type immediately available ; 9 . Disease criterion : Day 21 ( +/7 day ) bone marrow aspiration biopsy begin salvage DCIA : . In complete morphologic remission &lt; 5 % bone marrow blast , b. Aplastic ( &lt; 10 % bone marrow cellularity ) , cytopenic absolute neutrophil count ( ANC ) less 1,000/µL , c. Low disease burden &lt; 30 % BM blast , recovery peripheral blood ( PB ) WBC ( ANC &gt; 1,000/µL ) &lt; 5 % circulating blast . 10 . Adequate organ function criterion : a. Serum creatinine clearance &gt; /= 50 ml/min ( calculate Cockcroft Gault formula ) ; b . Total bilirubin &lt; /= 2 time upper limit normal ( x ULN ) ( 3 x ULN consider due leukemic involvement Gilbert 's syndrome ) ; c. Alanine aminotransferase ( ALT ) &lt; /= 3 x ULN ( 5.0 x ULN consider due leukemic involvement ) ; d. LVEF &gt; /= 40 % ECHO MUGA ; e. DLCO &gt; /= 50 % predicted correction hemoglobin ( must perform patient history smoke lung disease ; ) ; DLCO may omit patient without history pulmonary disease approve Study Chair . 11 . No active infection : Patients afebrile . If present , pulmonary infiltrates sit infection must improve antibiotic . Patients require oxygen . Study Chair arbiter criterion . 1 . HIV positive ; active hepatitis B C. 2 . Uncontrolled active infection ( viral , bacterial , fungal ) ; Study Chair final arbiter criterion . 3 . Patients active secondary malignancy unless approve Study Chair . 4 . Liver cirrhosis . 5 . Active CNS involvement within previous 2 month . 6 . Prior induction therapy DAC + CIA . 7 . Positive pregnancy test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 8 . Breast feeding woman . 9 . Men must agree father child agree use condom partner child bear potential . 10 . Inability comply medical therapy followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Refractory</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>AHSCT</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Total body irradiation</keyword>
	<keyword>TBI</keyword>
	<keyword>XRT</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG ( Rabbit )</keyword>
	<keyword>Rabbit antithymocyte Globulin</keyword>
	<keyword>Rabbit Antilymphocyte Globulin</keyword>
	<keyword>Rabbit ATG</keyword>
	<keyword>rATG</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
</DOC>